1 research outputs found
Abstract B37: RNAi and CRISPR/Cas9-based in vivo models for drug discovery
No full textAbstract
With the advent of RNAi and more recently CRISPR/Cas9 technologies, the speed and precision by which genetically engineered mouse models of cancer can be created is unprecedented. Having previously engineered a miRE scaffold for enhanced shRNA processing and now with the introduction of a powerful new SplashRNA algorithm for accurate shRNA prediction, we have brought RNAi technology to its peak by increasing potency and reducing off-target effects, such that it can be effectively exploited to preclinically mimic drug therapy and even combination therapy not only in vitro but also in live mice. Here, we take advantage of Cas9-expressing mice and demonstrate that in situ delivery of sgRNAs can lead to somatic mutagenesis to promote rapid tumorigenesis in mice. By combining this approach with inducible and reversible RNAi-mediated gene silencing to mimic drug therapy in the same mice, we now have an advanced platform to perform target validation and toxicity assessment of novel candidate targets in vivo. Here, we showcase how synergizing our RNAi and CRISPR/Cas9 genetic toolbox will help facilitate cancer drug discovery research and increase our confidence in predicting drug responses in humans into a new era.
Citation Format: Prem K. Premsrirut, Chia-Lin Wang, Yu-ting Yang, Rafii Pelossof, Christina Leslie, Christof Fellmann, Lukas Dow, Johannes Zuber, Scott Lowe. RNAi and CRISPR/Cas9-based in vivo models for drug discovery [abstract]. In: Proceedings of the AACR Special Conference: Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond; 2017 Sep 24-27; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(10 Suppl):Abstract nr B37.</jats:p
